Cost-Minimization Analysis of Biologic Disease-Modifying Antirheumatic Drugs Administered by Subcutaneous Injections in Patients with Rheumatoid Arthritis.
- Author:
Seung Hoo PARK
1
;
Min Young LEE
;
Eui Kyung LEE
Author Information
1. College of Pharmacy, Sungkyunkwan University, 2066, Seobu-ro, Jangan-gu, Suwon-si, Gyeong gi-do 16419, Republic of Korea. ekyung@skku.edu
- Publication Type:Original Article
- Keywords:
Biologic disease-modifying antirheumatic drugs;
rheumatoid arthritis;
subcutaneous injection;
cost-minimization analysis
- MeSH:
Antirheumatic Agents*;
Arthritis, Rheumatoid*;
Delivery of Health Care;
Health Care Costs;
Humans;
Injections, Subcutaneous*;
Outpatients;
Palliative Care;
Rheumatology;
Abatacept;
Adalimumab;
Etanercept
- From:Korean Journal of Clinical Pharmacy
2016;26(1):59-69
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: The subcutaneous formulation of biologic disease-modifying antirheumatic drugs (DMARDs) was preferred due to favored self-administration and would be an economical treatment option for patients with rheumatoid arthritis. This study was to compare the economic impact of biologic DMARDs administered by subcutaneous injection in patients with rheumatoid arthritis who had inadequate response to conventional DMARDs. METHODS: The cost-minimization analysis was conducted to estimate the lifetime health care costs of treatment sequences with subcutaneous biologic DMARDs as first-line therapy from a health care system perspective. The Markov model was developed to represent the transitions through treatment sequences based on American College of Rheumatology response rate and discontinuation rate. The health care costs comprised the cost of medications, administration, dispensing, outpatient visits, test/diagnostic examination, palliative therapy and treatment of serious infection. All costs were expressed in 2016 Korean Won (KRW) and discounted at 5%. RESULTS: The mean lifetime health care cost per patient was lowest in the etanercept sequence, which was estimated at KRW 63,441,679. The incremental costs of the treatment sequence started with adalimumab, golimumab, abatacept, and tocilizumab were KRW 7,985,730, KRW 4,064,669, KRW 2,869,947, and KRW 4,282,833, respectively, relative to etanercept sequence. These differences in costs mainly were attributable to medication costs. One-way and probabilistic sensitivity analyses confirmed that etanercept represented the option with the lowest cost compared with comparators. CONCLUSION: This study found that etanercept is likely a cost-saving treatment option among subcutaneous biologic DMARDs in patients with rheumatoid arthritis.
